
    
      Primary Objective:

      To assess the effectiveness of Thiotepa, Fludarabine, and Melphalan in alternative donor
      transplants as measured by leukemia free survival.

      Secondary Objective:

      To assess the 1- year OS, Relapse, TRM, aGVHD and cGVHD rates and the rates of neutrophil and
      platelet engraftment.

      Study Design This is a Phase II study of Thiotepa, Fludarabine, and Melphalan in alternative
      donor transplants.

      Subjects will be assessed for safety and tolerability (including adverse events, serious
      adverse events, and clinical/laboratory assessments) using a continuous monitoring approach.
      Subjects will be followed for up to 1 year or until progression of disease, relapse, or
      death.
    
  